BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

803 related articles for article (PubMed ID: 22401750)

  • 41. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients.
    Ben-Ami R; Rodríguez-Baño J; Arslan H; Pitout JD; Quentin C; Calbo ES; Azap OK; Arpin C; Pascual A; Livermore DM; Garau J; Carmeli Y
    Clin Infect Dis; 2009 Sep; 49(5):682-90. PubMed ID: 19622043
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Kim EC; Oh MD; Choe KW
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4574-81. PubMed ID: 15561828
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Extended-spectrum beta-lactamase-producing organisms.
    Falagas ME; Karageorgopoulos DE
    J Hosp Infect; 2009 Dec; 73(4):345-54. PubMed ID: 19596491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Countrywide spread of community- and hospital-acquired extended-spectrum beta-lactamase (CTX-M-15)-producing Enterobacteriaceae in Lebanon.
    Moubareck C; Daoud Z; Hakimé NI; Hamzé M; Mangeney N; Matta H; Mokhbat JE; Rohban R; Sarkis DK; Doucet-Populaire F
    J Clin Microbiol; 2005 Jul; 43(7):3309-13. PubMed ID: 16000453
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prevalence and risk factors of infections caused by extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae.
    Nakai H; Hagihara M; Kato H; Hirai J; Nishiyama N; Koizumi Y; Sakanashi D; Suematsu H; Yamagishi Y; Mikamo H
    J Infect Chemother; 2016 May; 22(5):319-26. PubMed ID: 26968486
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Rate of transmission of extended-spectrum beta-lactamase-producing enterobacteriaceae without contact isolation.
    Tschudin-Sutter S; Frei R; Dangel M; Stranden A; Widmer AF
    Clin Infect Dis; 2012 Dec; 55(11):1505-11. PubMed ID: 22955436
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.
    Mosqueda-Gómez JL; Montaño-Loza A; Rolón AL; Cervantes C; Bobadilla-del-Valle JM; Silva-Sánchez J; Garza-Ramos U; Villasís-Keever A; Galindo-Fraga A; Palacios GM; Ponce-de-León A; Sifuentes-Osornio J
    Int J Infect Dis; 2008 Nov; 12(6):653-9. PubMed ID: 18511321
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Enterobacter bacteremia: Clinical features, risk factors for multiresistance and mortality in a Chinese University Hospital.
    Ye Y; Li JB; Ye DQ; Jiang ZJ
    Infection; 2006 Oct; 34(5):252-7. PubMed ID: 17033748
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Extended-spectrum beta-lactamase-producing Enterobacteriaceae at Middlemore Hospital.
    Briggs S; Ussher J; Taylor S
    N Z Med J; 2005 Jul; 118(1218):U1563. PubMed ID: 16027752
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome.
    Ortega M; Marco F; Soriano A; Almela M; Martínez JA; Muñoz A; Mensa J
    J Antimicrob Chemother; 2009 Mar; 63(3):568-74. PubMed ID: 19126669
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Emergency Department Urinary Tract Infections Caused by Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae: Many Patients Have No Identifiable Risk Factor and Discordant Empiric Therapy Is Common.
    Frazee BW; Trivedi T; Montgomery M; Petrovic DF; Yamaji R; Riley L
    Ann Emerg Med; 2018 Oct; 72(4):449-456. PubMed ID: 29980462
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of extended-spectrum beta-lactamases in Enterobacteriaceae, Pseudomonas and Stenotrophomonas as determined by the VITEK 2 and E test systems in a Kuwait teaching hospital.
    Jamal W; Rotimi VO; Khodakhast F; Saleem R; Pazhoor A; Al Hashim G
    Med Princ Pract; 2005; 14(5):325-31. PubMed ID: 16103698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Extended-spectrum beta-lactamase-producing phenotype signifies a poor prognosis for patients with cefpodoxime-resistant Escherichia coli or Klebsiella pneumoniae bacteremia.
    Lee CI; Lee NY; Yan JJ; Lee HC; Ko NY; Chang CM; Wu CJ; Chen PL; Wang LR; Ko WC
    J Microbiol Immunol Infect; 2009 Aug; 42(4):303-9. PubMed ID: 19949753
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections].
    Hallgren H; Gustafsson I; Ripa T
    Lakartidningen; 2007 Dec; 104(51-52):3883-5. PubMed ID: 18232531
    [No Abstract]   [Full Text] [Related]  

  • 56. Clinical Risk Score for Prediction of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Bloodstream Isolates.
    Augustine MR; Testerman TL; Justo JA; Bookstaver PB; Kohn J; Albrecht H; Al-Hasan MN
    Infect Control Hosp Epidemiol; 2017 Mar; 38(3):266-272. PubMed ID: 27989244
    [TBL] [Abstract][Full Text] [Related]  

  • 57. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
    Marchaim D; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Sprecher H; Lachish T; Wiener-Well Y; Alon D; Chowers M; Ciobotaro P; Bardenstein R; Paz A; Potasman I; Giladi M; Schechner V; Schwaber MJ; Klarfeld-Lidji S; Carmeli Y
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5099-104. PubMed ID: 20837757
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beta-lactam/beta-lactamase inhibitors versus carbapenem for bloodstream infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: systematic review and meta-analysis.
    Sfeir MM; Askin G; Christos P
    Int J Antimicrob Agents; 2018 Nov; 52(5):554-570. PubMed ID: 30081138
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Extended-spectrum beta-lactamases and clinical outcomes: current data.
    Ramphal R; Ambrose PG
    Clin Infect Dis; 2006 Apr; 42 Suppl 4():S164-72. PubMed ID: 16544267
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical features of nosocomial infections by extended-spectrum beta-lactamase-producing Enterobacteriaceae in neonatal intensive care units.
    Chiu S; Huang YC; Lien RI; Chou YH; Lin TY
    Acta Paediatr; 2005 Nov; 94(11):1644-9. PubMed ID: 16303704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 41.